Metagenomi, Inc. (MGX)
Market Cap | 158.47M |
Revenue (ttm) | 47.26M |
Net Income (ttm) | -77.27M |
Shares Out | 37.46M |
EPS (ttm) | -2.06 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 39,325 |
Open | 4.430 |
Previous Close | 4.420 |
Day's Range | 4.150 - 4.440 |
52-Week Range | 3.340 - 12.740 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 17.83 (+321.51%) |
Earnings Date | Aug 12, 2024 |
About MGX
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based th... [Read more]
Financial Performance
In 2023, Metagenomi's revenue was $44.76 million, an increase of 160.21% compared to the previous year's $17.20 million. Losses were -$68.26 million, 56.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price forecast is $17.83, which is an increase of 321.51% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/q/e/conf16-2452469.jpg)
Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference
EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its propriet...
![](https://cdn.snapi.dev/images/v1/3/b/press4-2430668.jpg)
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024;...
![](https://cdn.snapi.dev/images/v1/l/l/press2-2404106.jpg)
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
Enhances strategic flexibility and control of key gene editing technologies and programs Enhances strategic flexibility and control of key gene editing technologies and programs
![](https://cdn.snapi.dev/images/v1/q/n/conf3-2360763.jpg)
Metagenomi to Present at Upcoming Scientific Meetings
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EM...
![](https://cdn.snapi.dev/images/v1/s/n/press14-2343938.jpg)
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024
![](https://cdn.snapi.dev/images/v1/g/g/press12-2302413.jpg)
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients ...
![](https://cdn.snapi.dev/images/v1/k/h/press7-2274620.jpg)
Metagenomi Announces Closing of Initial Public Offering
EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprie...
![](https://cdn.snapi.dev/images/v1/r/d/drugs36-2269978.jpg)
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.
![](https://cdn.snapi.dev/images/v1/7/i/7imtr-2268802.jpg)
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln
Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its ...
![](https://cdn.snapi.dev/images/v1/p/r/press19-2268767.jpg)
Metagenomi Announces Pricing of Initial Public Offering
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients us...
![](https://stockanalysis.com/img/news/nasdaq4.jpg)
Moderna, Bayer-backed startup Metagenomi files for US IPO
Metagenomi Technologies, a genetic medicines company backed by Bayer Healthcare and Moderna , filed for an initial public offering (IPO) in the United States on Friday.
![](https://stockanalysis.com/img/news/wall-street-2.jpg)
Gene editing biotech Metagenomi files for a $100 million IPO
Metagenomi, a preclinical biotech developing therapies using metagenomics-derived genome editing, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
![](https://stockanalysis.com/img/news/ipo2.jpg)
Metagenomi IPO Registration Document (S-1)
Metagenomi has filed to go public with an IPO on the NASDAQ.